Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 172M | 53M | 161M | 112M | 107M |
| Gross Profit | 79M | 11M | 80M | 26M | 15M |
| Operating Income | -4M | -8M | 1M | -3M | -12M |
| EBITDA | -2M | -5M | 3M | -9K | -3M |
| Net Income | -6M | -10M | 2M | -5M | -3M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$11.41
+2.98% today
1Y Change
+31.27%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Star Equity Holdings, Inc. (STRR) is a Healthcare stock with a market cap of $40.00M and listed on NASDAQ. The stock last traded around $11.41 and up 31.3% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +222.6%, EPS growth of +47.6%, a dividend yield of 0.0%. What stands out right now is revenue +222.6%, EPS +47.6%, free cash flow -11.5% with operating margin -3.1% and ROIC -5.0%. Valuation is more restrained than many high-expectation growth names at price/sales 0.2. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines STRR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
STRR
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
STRR Max Drawdown
-21.68%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for STRR and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$106.6M
-5.0% YoY
FY Net Income
-$3.0M
+43.2% YoY
Free Cash Flow
-$7.2M
-43.4% YoY
Revenue Growth
+222.6%
EPS Growth
+47.6%
Gross Margin
43.0%
Net Margin
-3.5%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 172M | 53M | 161M | 112M | 107M |
| Gross Profit | 79M | 11M | 80M | 26M | 15M |
| Operating Income | -4M | -8M | 1M | -3M | -12M |
| EBITDA | -2M | -5M | 3M | -9K | -3M |
| Net Income | -6M | -10M | 2M | -5M | -3M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 12M | 17M | 23M | 27M | 22M |
| Total Assets | 113M | 53M | 61M | 68M | 61M |
| Total Liabilities | 48M | 12M | 12M | 22M | 22M |
| Shareholder Equity | 66M | 40M | 49M | 46M | 39M |
| Total Debt | 26M | 1M | 1M | 2M | 2M |
| Net Debt | 14M | -16M | -21M | -25M | -19M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
6M
-67.2% YoY
Capital Expenditures
788K
+33.7% YoY
Free Cash Flow
7M
-43.4% YoY
Key ratios
Gross Margin
43.0%
Operating Margin
-3.1%
Net Margin
-3.5%
ROE
-10.0%
Debt / Equity
0.40x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.